Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA.
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, Weill Cornell Medical College, New York, NY, USA.
Eur Urol. 2018 Oct;74(4):465-471. doi: 10.1016/j.eururo.2018.04.030. Epub 2018 May 18.
Open radical cystectomy (ORC) has proven to be an important component in the treatment of high-risk bladder cancer (BCa). ORC surgical morbidity remains high; therefore, minimally invasive surgical techniques have been introduced in an attempt to improve patient outcomes.
To compare cancer outcomes in BCa patients managed with ORC or robotic-assisted radical cystectomy (RARC).
DESIGN, SETTING, AND PARTICIPANTS: A prospective, randomized trial was completed between 2010 and 2013. Patients were randomized to ORC/pelvic lymphadenectomy (PLND) or RARC/PLND, with all undergoing open/extracorporeal urinary diversion. Median follow-up was 4.9 (IQR: 3.9-5.9) yr after surgery among surviving patients.
Secondary outcomes to the trial included recurrence-free, cancer-specific, and overall survival.
The trial randomized 118 patients who underwent RC/PLND and urinary diversion. Sixty were randomized to RARC and 58 to ORC. Four RARC-assigned patients refused randomization and received ORC; however, an intention to treat analysis was performed. No differences were observed in recurrence (hazard ratio [HR]: 1.27; 95% confidence interval [CI]: 0.69-2.36; p=0.4) or cancer-specific survival (p=0.4). No difference in overall survival was observed (p=0.8). However, the pattern of first recurrence demonstrated a nonstatistically significant increase in metastatic sites for those undergoing ORC (sub-HR [sHR]: 2.21; 95% CI: 0.96-5.12; p=0.064) and a greater number of local/abdominal sites in the RARC-treated patients (sHR: 0.34; 95% CI: 0.12-0.93; p=0.035). The major limitation to this study is that the trial was not powered to determine differences in cancer recurrences, survival outcomes, or patterns of recurrence.
The secondary outcomes from our randomized trial did not definitively demonstrate differences in cancer outcomes in patients treated with ORC or RARC. However, differences in observed patterns of first recurrence highlight the need for future studies.
Of 118 patients randomly assigned to undergo radical cystectomy/pelvic lymphadenectomy and urinary diversion, half were assigned to open surgery and half to robot-assisted techniques. We found no difference in risk of recurring or dying of bladder cancer between the two groups.
开放性根治性膀胱切除术(ORC)已被证明是治疗高危膀胱癌(BCa)的重要组成部分。ORC 手术发病率仍然很高;因此,已经引入了微创外科技术,试图改善患者的预后。
比较接受 ORC 或机器人辅助根治性膀胱切除术(RARC)治疗的 BCa 患者的癌症结局。
设计、设置和参与者:一项前瞻性、随机试验于 2010 年至 2013 年完成。患者被随机分配接受 ORC/盆腔淋巴结清扫术(PLND)或 RARC/PLND,所有患者均接受开放性/体外尿路转流术。在接受手术的存活患者中,中位随访时间为术后 4.9(IQR:3.9-5.9)年。
试验的次要结局包括无复发生存、癌症特异性生存和总体生存。
该试验随机分配了 118 例接受 RC/PLND 和尿路转流术的患者。60 例被随机分配到 RARC 组,58 例被随机分配到 ORC 组。4 例 RARC 分配的患者拒绝随机分组并接受 ORC,但进行了意向治疗分析。在复发(危险比[HR]:1.27;95%置信区间[CI]:0.69-2.36;p=0.4)或癌症特异性生存(p=0.4)方面未观察到差异。在总生存方面未观察到差异(p=0.8)。然而,首次复发的模式显示,接受 ORC 的患者转移部位的复发率非统计学显著增加(亚 HR[sHR]:2.21;95%CI:0.96-5.12;p=0.064),而接受 RARC 治疗的患者局部/腹部部位的复发率更高(sHR:0.34;95%CI:0.12-0.93;p=0.035)。本研究的主要局限性是该试验没有足够的效力来确定 ORC 或 RARC 治疗患者的癌症复发、生存结局或复发模式的差异。
我们的随机试验的次要结局并未明确证明接受 ORC 或 RARC 治疗的患者在癌症结局方面存在差异。然而,首次复发模式的差异突出表明需要进一步研究。
在 118 例随机分配接受根治性膀胱切除术/盆腔淋巴结清扫术和尿路转流术的患者中,一半接受开放性手术,一半接受机器人辅助技术。我们没有发现两组之间膀胱癌复发或死亡风险的差异。